Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CTNM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.71
1 Year Target Price $23.71
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.55% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.42M USD | Price to earnings Ratio - | 1Y Target Price 23.71 |
Price to earnings Ratio - | 1Y Target Price 23.71 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 3.35 - 21.92 | Updated Date 07/13/2025 |
52 Weeks Range 3.35 - 21.92 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.95% | Return on Equity (TTM) -33.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -83291529 | Price to Sales(TTM) 11.15 |
Enterprise Value -83291529 | Price to Sales(TTM) 11.15 | ||
Enterprise Value to Revenue 8.25 | Enterprise Value to EBITDA 20.76 | Shares Outstanding 19142400 | Shares Floating 13167066 |
Shares Outstanding 19142400 | Shares Floating 13167066 | ||
Percent Insiders 1.82 | Percent Institutions 79.99 |
Upturn AI SWOT
Contineum Therapeutics, Inc. Class A Common Stock
Company Overview
History and Background
Contineum Therapeutics, Inc., formerly known as Vitae Pharmaceuticals, Inc., was founded in 2018. It focuses on developing novel therapies targeting specific biological pathways to treat unmet medical needs in neuroinflammation, neurodegeneration, and immunology. Initial focus was on treatments of Parkinson's and Multiple Sclerosis
Core Business Areas
- Neuroinflammation: Focuses on developing therapies that address inflammation in the nervous system, potentially impacting conditions like multiple sclerosis.
- Neurodegeneration: Develops treatments aimed at preventing or slowing the progression of neurodegenerative diseases like Parkinson's disease.
- Immunology: Develops therapies to treat a variety of immune mediated diseases.
Leadership and Structure
The leadership team includes executives with extensive experience in pharmaceutical research, development, and commercialization. Organizational structure typically includes departments for research and development, clinical trials, regulatory affairs, and business development. The CEO is Dewey Steadman.
Top Products and Market Share
Key Offerings
- PAC-14028: A small molecule MRS1967 agonist designed to be highly selective for subtype 4 of the metabotropic glutamate receptor (M4), which is a G protein-coupled receptor. Currently in Phase 2 clinical trials for multiple sclerosis. Competitors include companies developing other MS therapies, such as Biogen (BIIB) and Novartis (NVS).
- PAC-812: A selective inhibitor of the LPA1 receptor for Parkinson's Disease and Progressive Supranuclear Palsy. Competitors include companies developing Parkinson's and PSP therapies, such as Biogen (BIIB), Roche (RHHBY) and UCB.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. There's growing demand for innovative therapies targeting neurological disorders and immunological diseases.
Positioning
Contineum Therapeutics is positioned as a clinical-stage biotechnology company focused on novel therapies. Competitive advantages potentially include its targeted approach to modulating specific biological pathways.
Total Addressable Market (TAM)
The total addressable market for neuroinflammatory, neurodegenerative, and immunological diseases is substantial, estimated to be hundreds of billions of dollars annually. Contineum's positioning in specific disease areas allows it to capture a segment of this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Experienced management team
- Strong intellectual property portfolio
- Clinical-stage pipeline
Weaknesses
- Dependence on clinical trial outcomes
- High R&D expenditure
- Limited commercial infrastructure
- Competition from larger pharmaceutical companies
Opportunities
- Successful clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Novartis (NVS)
- Roche (RHHBY)
- UCB (UCBJF)
Competitive Landscape
Contineum Therapeutics faces competition from established pharmaceutical companies with greater resources and commercial infrastructure. Its competitive advantage lies in its novel therapeutic targets and selective approaches.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D investment and advancement of clinical programs.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates would be required for specific projections.
Recent Initiatives: Recent initiatives include advancing PAC-14028 and PAC-812 through clinical trials, seeking partnerships, and optimizing its drug discovery platform.
Summary
Contineum Therapeutics is a clinical-stage biotech company with promising novel therapies in the neuroinflammation and neurodegeneration spaces. The company's success is heavily dependent on the outcome of its clinical trials. Securing partnerships with larger pharmaceutical companies could provide significant resources and validation. Risks include clinical trial failures and competition from established players. Overall, Contineum is a high-risk, high-reward investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Contineum Therapeutics, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-04-05 | President, CEO & Director Mr. Carmine N. Stengone MBA, MS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.contineum-tx.com |
Full time employees 41 | Website https://www.contineum-tx.com | ||
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.